You are here

Article info

Article menu
Original Article
A Phase 2 study of cisplatin analog CI-973 in the treatment of patients with refractory, advanced ovarian cancer

Authors

  • J.A. Roberts Division of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan, †Section of Gynecologic Medical Oncology, M.D. Anderson Cancer Center, Houston, Texas, ‡Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, §Kenneth Norris Comprehensive Cancer Center, University of Southern California, Los Angeles,¶Section of Gynecologic Oncology, Northwestern University Medical School, Chicago, Illinois and **Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan, USA PubMed articlesGoogle scholar articles
  • A. P. Kudelka Division of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan, †Section of Gynecologic Medical Oncology, M.D. Anderson Cancer Center, Houston, Texas, ‡Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, §Kenneth Norris Comprehensive Cancer Center, University of Southern California, Los Angeles,¶Section of Gynecologic Oncology, Northwestern University Medical School, Chicago, Illinois and **Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan, USA PubMed articlesGoogle scholar articles
  • D. R. Spriggs Division of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan, †Section of Gynecologic Medical Oncology, M.D. Anderson Cancer Center, Houston, Texas, ‡Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, §Kenneth Norris Comprehensive Cancer Center, University of Southern California, Los Angeles,¶Section of Gynecologic Oncology, Northwestern University Medical School, Chicago, Illinois and **Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan, USA PubMed articlesGoogle scholar articles
  • F. Muggia Division of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan, †Section of Gynecologic Medical Oncology, M.D. Anderson Cancer Center, Houston, Texas, ‡Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, §Kenneth Norris Comprehensive Cancer Center, University of Southern California, Los Angeles,¶Section of Gynecologic Oncology, Northwestern University Medical School, Chicago, Illinois and **Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan, USA PubMed articlesGoogle scholar articles
  • J. Lurain Division of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan, †Section of Gynecologic Medical Oncology, M.D. Anderson Cancer Center, Houston, Texas, ‡Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, §Kenneth Norris Comprehensive Cancer Center, University of Southern California, Los Angeles,¶Section of Gynecologic Oncology, Northwestern University Medical School, Chicago, Illinois and **Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan, USA PubMed articlesGoogle scholar articles
  • W. Grove Division of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan, †Section of Gynecologic Medical Oncology, M.D. Anderson Cancer Center, Houston, Texas, ‡Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, §Kenneth Norris Comprehensive Cancer Center, University of Southern California, Los Angeles,¶Section of Gynecologic Oncology, Northwestern University Medical School, Chicago, Illinois and **Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan, USA PubMed articlesGoogle scholar articles
  • C. Kowal Division of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan, †Section of Gynecologic Medical Oncology, M.D. Anderson Cancer Center, Houston, Texas, ‡Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, §Kenneth Norris Comprehensive Cancer Center, University of Southern California, Los Angeles,¶Section of Gynecologic Oncology, Northwestern University Medical School, Chicago, Illinois and **Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan, USA PubMed articlesGoogle scholar articles
  1. Address for correspondence: Dr J. A. Roberts, Division of Gynecologic Oncology, D2246 Medical Professional Building, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109-0718, USA.

Citation

Roberts J, Kudelka AP, Spriggs DR, et al
A Phase 2 study of cisplatin analog CI-973 in the treatment of patients with refractory, advanced ovarian cancer
International Journal of Gynecologic Cancer 1996;6:257-260.

Publication history

  • First published July 1, 1996.
Online issue publication 
December 03, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

International Gynecologic Cancer Society